Olverembatinib-Based Immunotherapy Shows Promise in Ph+ ALL
A retrospective comparison from Peking University People’s Hospital found that pairing olverembatinib with antibody-based immunotherapy produced encouraging response and survival signals as an alternative to transplantation in Ph+ ALL. The analysis supports further evaluation…
